Developing a novel biologic therapy for achondroplasia, the most common form of dwarfism
- Year invested 2015
- Investment Stage Early
- Sectors
- Investment Status Historic
- Website therachon.com/
- Company Status Private
Developing a novel biologic therapy for achondroplasia, the most common form of dwarfism